Gilead Sciences Q3 2026 net income falls 20% to $2.43 billion; Q3 2026 total revenues rise 7% to $8.3 billion

• Gilead Sciences’ third-quarter 2026 diluted earnings per share fell 20% year-over-year to $1.94, partly due to equity securities losses.
• Product sales rose 13% to $8.29 billion, primarily driven by HIV treatments, Trodelvy and Livdelzi.
• HIV product sales climbed 18% to $6.25 billion, supported by higher realized prices, prevention demand and favorable inventory dynamics.
• Bixlenvo received FDA approval as a single-tablet HIV treatment for virologically suppressed adults switching from existing regimens.
• Full-year 2026 guidance projects a diluted loss of $4.05–$4.40 per share and product sales of $31 billion–$31.3 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261029068948) on October 29, 2026, and is solely responsible for the information contained therein.